Myriad Genetics vs Bio-Techne
MYGN and TECH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MYGN and TECH compare
Bio-Techne is the larger company, worth 21 times as much as Myriad Genetics ($11.4B against $541M).
Bio-Techne grew revenue faster over the last twelve months (0.94% versus −2.6% for Myriad Genetics).
Bio-Techne pays a dividend yielding 0.55%; Myriad Genetics does not pay one.
Bio-Techne scores higher on the StockData Score (11 against 5 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MYGN | TECH |
|---|---|---|
| Size and price | ||
| Market cap | $541M | $11.4B |
| Share price | $5.66 | $72.80 |
| Change, 1 year | −13.5% | 18.6% |
| Change, 5 years | −79.8% | −41.9% |
| Beta (5Y) | 1.54 | 1.07 |
| Employees | 2,700 | 3,000 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 66.8× |
| P/S | 0.7× (better) | 9.3× |
| P/B | 2.0× (better) | 5.3× |
| EV/EBITDA | – | 33.4× |
| P/FCF | – | 37.1× |
| FCF yield | – | 2.7% |
| Fair value | – | $51.93 |
| Margin of safety | – | −40.2% |
| Growth | ||
| Revenue growth (TTM) | −2.6% | 0.94% (better) |
| Revenue growth, 5Y average | −0.63% | 5.5% (better) |
| EPS growth (TTM) | – | 122% |
| EPS growth, 5Y average | – | 5.9% |
| Profitability | ||
| Gross margin | 68.3% (better) | 65.8% |
| Operating margin | −14.3% | 19.6% (better) |
| Net margin | −16.1% | – |
| FCF margin | – | 25.1% |
| Return on equity | −40.2% | – |
| Return on invested capital | −28.9% | 8.8% (better) |
| Financial health | ||
| Debt / equity | 0.45 | 0.09 (better) |
| Net debt / EBITDA | – | −0.44 |
| Interest coverage | −6.9× | 27.2× (better) |
| Current ratio | 1.98 | 2.28 (better) |
| Altman Z-score | −0.94 | 16.15 (better) |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 0.55% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 0.55% (better) |
| Ownership | ||
| Held by institutions | 94.1% | 112% |
| Held by insiders | 7.2% | 0.36% |
| Insider net buying, 12 months | $655K (better) | −$437K |
| Superinvestors holding | – | 4 |
| Short interest, % of float | 9.5% | 4.9% |
Go deeper
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
- TECH stock overview
- TECH income statement
- TECH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.